NASDAQ:ALVR AlloVir (ALVR) Stock Price, News & Analysis $3.20 +0.04 (+1.27%) As of 09/18/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC Filings About AlloVir Stock (NASDAQ:ALVR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AlloVir alerts:Sign Up Key Stats Today's Range$3.04▼$3.2350-Day Range$3.16▼$4.8252-Week Range$7.96▼$24.15Volume234,394 shsAverage Volume15,685 shsMarket Capitalization$16.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview AlloVir, Inc. was a biotechnology company focused on developing allogeneic, virus-specific T-cell therapies for people whose immune systems are compromised, including recipients of organ or stem-cell transplants. Its research sought to address serious viral infections that can occur when patients cannot mount an effective immune response. The company’s leading investigational product was posoleucel, also known as ALVR105, an “off-the-shelf” multivirus-specific T-cell therapy designed to target several viruses, including cytomegalovirus, Epstein-Barr virus, adenovirus, BK virus and human herpesvirus 6. AlloVir evaluated posoleucel in clinical studies involving immunocompromised patients and also investigated additional T-cell products directed at individual viral infections. AlloVir was headquartered in Waltham, Massachusetts, and was founded on technology associated with ViraCyte, a company specializing in virus-specific T-cell therapies. In late 2023, AlloVir announced that it was discontinuing development of posoleucel after disappointing results from a pivotal study and was pursuing strategic alternatives. The company’s programs primarily targeted patients and healthcare providers in the United States and other markets served through clinical research and development activities.AI Generated. May Contain Errors. Read More Receive ALVR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALVR Stock News HeadlinesKLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) StockholdersAugust 3, 2026 | globenewswire.comALLOVIR INVESTIGATION: Bragar Eagel & Squire, P.C. Continues Investigation into AlloVir, Inc. on Behalf of Long-Term StockholdersOctober 16, 2025 | globenewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 19 at 1:00 AM | InvestorPlace (Ad)ALLOVIR ALERT: Bragar Eagel & Squire, P.C. is Investigating AlloVir, Inc. ...August 6, 2025 | gurufocus.comALLOVIR ALERT: Bragar Eagel & Squire, P.C. is Investigating AlloVir, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmAugust 6, 2025 | globenewswire.comKalaris Announces Closing of Merger with AlloVirMarch 18, 2025 | globenewswire.comAlloVir shareholders approve merger with Kalaris TherapeuticsMarch 14, 2025 | investing.comAlloVir, Inc.: Kalaris and AlloVir Announce Stockholder Approval of MergerMarch 13, 2025 | finanznachrichten.deSee More Headlines ALVR Stock Analysis - Frequently Asked Questions How have ALVR shares performed this year? AlloVir's stock was trading at $8.44 at the beginning of the year. Since then, ALVR shares have decreased by 62.1% and is now trading at $3.20. How were AlloVir's earnings last quarter? AlloVir, Inc. (NASDAQ:ALVR) released its earnings results on Wednesday, August, 14th. The company reported ($1.15) EPS for the quarter, beating the consensus estimate of ($2.30) by $1.15. When did AlloVir's stock split? AlloVir's stock reverse split on Thursday, January 16th 2025.The 1-23 reverse split was announced on Wednesday, January 15th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did AlloVir IPO? AlloVir (ALVR) raised $276 million in an initial public offering on Thursday, July 30th 2020. The company issued 16,250,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO. How do I buy shares of AlloVir? Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AlloVir own? Based on aggregate information from My MarketBeat watchlists, some other companies that AlloVir investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/14/2024Today9/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALVR CIK1754068 Webwww.allovir.com Phone617-433-2605FaxN/AEmployees110Year Founded2013Profitability EPS (Trailing Twelve Months)($20.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$190.42 million Net MarginsN/A Pretax MarginN/A Return on Equity-71.03% Return on Assets-61.27% Debt Debt-to-Equity RatioN/A Current Ratio86.78 Quick Ratio86.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$29.35 per share Price / Book0.11Miscellaneous Outstanding Shares5,043,000Free Float3,425,000Market Cap$16.14 million OptionableNo Data Beta0.63 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:ALVR) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
